Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 1/20 | 0.44 |
| ▸ | CTSB | P07858 | 1/20 | 0.44 |
| ▸ | CTSK | P43235 | 1/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.43 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.43 |
| ▸ | DPP4 | P27487 | 1/20 | 0.43 |
| ▸ | AGTR2 | P50052 | 2/20 | 0.43 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.41 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.41 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
| ▸ | SLC18A3 | Q16572 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4175726 | 1.00 | CTSL (0.44) | CTSLCTSBCTSKOPRM1OPRL1 | |
| SCHEMBL5711147 | 1.00 | CTSL (0.44) | CTSLCTSBCTSKOPRM1OPRL1 | |
| SCHEMBL24242210 | 1.00 | CTSL (0.44) | CTSLCTSBCTSKOPRM1OPRL1 | |
| SCHEMBL12640946 | 0.90 | SLC18A3 (0.48) | CTSLCTSBCTSKOPRM1OPRL1 | |
| SCHEMBL1288244 | 0.90 | SLC18A3 (0.48) | CTSLCTSBCTSKOPRM1OPRL1 | |
| SCHEMBL19914171 | 0.90 | SLC18A3 (0.48) | CTSLCTSBCTSKOPRM1OPRL1 | |
| SCHEMBL20178569 | 0.90 | SLC18A3 (0.48) | CTSLCTSBCTSKOPRM1OPRL1 | |
| SCHEMBL19067383 | 0.90 | OPRM1 (0.49) | CTSLCTSBCTSKOPRM1OPRL1 | |
| SCHEMBL426503 | 0.84 | CTSL (0.50) | CTSLCTSBCTSKOPRM1OPRL1 | |
| SCHEMBL989536 | 0.84 | CTSL (0.50) | CTSLCTSBCTSKOPRM1OPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11708319-B2 | Biphenyl amides with modified ether groups as HSP90 inhibitors and HSP70 inducers | UNIVERSITY OF KANSAS (US) | 2023-07-25 | — | — | US | disclosed |
| US-20200270201-A1 | BIPHENYL AMIDES WITH MODIFIED ETHER GROUPS AS HSP90 INHIBITORS AND HSP70 INDUCERS | REATA PHARMACEUTICALS, INC. | 2020-08-27 | — | — | US | disclosed |
| US-20120053180-A1 | CYCLOHEXANE ANALOGUES AS GPR119 AGONISTS | CHEMIZON, A DIVISION OF OPTOMAGIC CO., LTD. (KR) | 2012-03-01 | — | — | US | disclosed |
| US-20120053180-A1 | CYCLOHEXANE ANALOGUES AS GPR119 AGONISTS | CHEMIZON, A DIVISION OF OPTOMAGIC CO., LTD. (KR) | 2012-03-01 | — | — | US | disclosed |
| EP-1599433-B1 | METHOD FOR PRODUCING THE ENANTIOMERIC FORMS OF CIS 1,3-CYCLOHEXANEDIOL DERIVATIVES | SANOFI AVENTIS DEUTSCHLAND (DE) | 2006-12-06 | — | — | EP | disclosed |
| US-7094795-B2 | Process for preparing the enantiomeric forms of cis-configured 1,3-cyclohexanediol derivatives | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2006-08-22 | — | — | US | disclosed |
| EP-1599433-A1 | METHOD FOR PRODUCING THE ENANTIOMERIC FORMS OF CIS 1,3-CYCLOHEXANEDIOL DERIVATIVES | Sanofi-Aventis Deutschland GmbH (DE) | 2005-11-30 | — | — | EP | disclosed |
| US-20040209931-A1 | Process for preparing the enantiomeric forms of cis-configured 1,3-cyclohexanediol derivatives | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-10-21 | — | — | US | disclosed |
| WO-2004076390-A1 | METHOD FOR PRODUCING THE ENANTIOMERIC FORMS OF CIS 1,3-CYCLOHEXANEDIOL DERIVATIVES | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-09-10 | — | — | WO | disclosed |
| US-5942614-A | CHEMICAL INTERMEDIATE 7-CHLORO-5-(2-FLUOROPHENYL)-2,3-DIHYDRO-1H-1,4-BENZODIAZEPINE-2-METHANAMINE -4-OXIDE | PHARMACIA & UPJOHN COMPANY (US) | 1999-08-24 | — | — | US | disclosed |
| US-5922892-A | Process to produce midazolam | PHARMACIA & UPJOHN COMPANY (US) | 1999-07-13 | — | — | US | disclosed |
| EP-0918773-A1 | PROCESS FOR THE PRODUCTION OF 8-CHLORO-6-(2-FLUOROPHENYL)-1-METHYL-4H-IMIDAZO 1,5-A]BENZODIAZEPINE | PHARMACIA & UPJOHN COMPANY (US) | 1999-06-02 | — | — | EP | disclosed |
| US-5831089-A | Process to produce midazolam | PHARMACIA & UPJOHN COMPANY (US) | 1998-11-03 | — | — | US | disclosed |
| WO-1998000427-A1 | PROCESS FOR THE PRODUCTION OF 8-CHLORO-6-(2-FLUOROPHENYL)-1-METHYL-4H-IMIDAZO[1,5-A]BENZODIAZEPINE | PHARMACIA & UPJOHN COMPANY (US) | 1998-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11708319-B2 | Biphenyl amides with modified ether groups as HSP90 inhibitors and HSP70 inducers | HSP90AB2P, HSP90AB1, HSPB1 | CTSL 4828/4885CTSB 4099/4885CTSK 4746/4885 |
| US-20200270201-A1 | BIPHENYL AMIDES WITH MODIFIED ETHER GROUPS AS HSP90 INHIBITORS AND HSP70 INDUCERS | HSP90AB2P, HSP90AB1, HSPB1 | CTSL 4828/4885CTSB 4099/4885CTSK 4746/4885 |
| US-20040209931-A1 | Process for preparing the enantiomeric forms of cis-configured 1,3-cyclohexanediol derivatives | CYP1A1, CYP51A1, CYP1B1 | CTSL 426/4885CTSB 757/4885CTSK 898/4885 |
| US-20120053180-A1 | CYCLOHEXANE ANALOGUES AS GPR119 AGONISTS | GPR119, GLP1R, GIPR | CTSL 1664/4885CTSB 1268/4885CTSK 1604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.